Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.

Journal Article (Clinical Trial;Journal Article)

In January, 1972, the Southwest Oncology Group initiated two randomized studies for patients with advanced breast cancer. The study for patients with prior chemotherapy showed a 33% response rate with adriamycin. The study for patients without previous chemotherapy consisted of three treatment regimens; a weekly repeated combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone; these same five drugs given in courses of 5 days repeated every 4 weeks; and adriamycin as a single agent every 3 weeks. For the 283 evaluable patients, the response rates were: weekly combination 63/106 (59%); intermittent combination 39/98 (40%); and adriamycin 31/79 (39%). The median duration of response was 8 months for weekly combination, 10 months for intermittent therapy and only 4 months for adriamycin. Leukopenia was the dose-limiting toxicity with all three regimens. The weekly combination is the most effective therapy for patients with advanced disease. Extensive trails of combinations that include adriamycin are underway.

Full Text

Duke Authors

Cited Authors

  • Hoogstraten, B; George, SL; Samal, B; Rivkin, SE; Costanzi, JJ; Bonnet, JD; Thigpen, T; Braine, H

Published Date

  • July 1976

Published In

Volume / Issue

  • 38 / 1

Start / End Page

  • 13 - 20

PubMed ID

  • 947510

International Standard Serial Number (ISSN)

  • 0008-543X

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(197607)38:1<13::aid-cncr2820380104>;2-5


  • eng

Conference Location

  • United States